| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 26/04/2024 | 22:05 | Business Wire | bluebird bio Announces Receipt of Expected Notice from Nasdaq | NASDAQ:BLUE | bluebird bio Inc |
| 26/04/2024 | 11:45 | PR Newswire (US) | BLUE LAWSUIT ALERT: The Gross Law Firm Notifies bluebird bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline | NASDAQ:BLUE | bluebird bio Inc |
| 19/04/2024 | 11:45 | PR Newswire (US) | bluebird bio, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - BLUE | NASDAQ:BLUE | bluebird bio Inc |
| 16/04/2024 | 11:45 | PR Newswire (US) | Class Action Filed Against bluebird bio, Inc. (BLUE) Seeking Recovery for Investors - Contact The Gross Law Firm | NASDAQ:BLUE | bluebird bio Inc |
| 12/04/2024 | 11:45 | PR Newswire (US) | Shareholders that lost money on bluebird bio, Inc.(BLUE) Urged to Join Class Action - Contact The Gross Law Firm to Learn More | NASDAQ:BLUE | bluebird bio Inc |
| 11/04/2024 | 14:00 | Business Wire | bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:BLUE | bluebird bio Inc |
| 09/04/2024 | 11:45 | PR Newswire (US) | bluebird bio, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before May 28, 2024 to Discuss Your Rights - BLUE | NASDAQ:BLUE | bluebird bio Inc |
| 05/04/2024 | 11:45 | PR Newswire (US) | Shareholders that lost money on bluebird bio, Inc.(BLUE) should contact The Gross Law Firm about pending Class Action - BLUE | NASDAQ:BLUE | bluebird bio Inc |
| 26/03/2024 | 12:01 | Business Wire | bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance | NASDAQ:BLUE | bluebird bio Inc |
| 25/03/2024 | 21:05 | Business Wire | bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call | NASDAQ:BLUE | bluebird bio Inc |
| 18/03/2024 | 13:00 | Business Wire | bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital | NASDAQ:BLUE | bluebird bio Inc |
| 11/03/2024 | 13:00 | Business Wire | bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy | NASDAQ:BLUE | bluebird bio Inc |
| 05/03/2024 | 23:40 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:BLUE | bluebird bio Inc |
| 14/02/2024 | 19:54 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:BLUE | bluebird bio Inc |
| 08/01/2024 | 22:35 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:BLUE | bluebird bio Inc |
| 08/01/2024 | 14:03 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:BLUE | bluebird bio Inc |
| 08/01/2024 | 14:00 | Business Wire | bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook | NASDAQ:BLUE | bluebird bio Inc |
| 02/01/2024 | 14:00 | Business Wire | bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference | NASDAQ:BLUE | bluebird bio Inc |
| 20/12/2023 | 23:05 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:BLUE | bluebird bio Inc |
| 20/12/2023 | 03:41 | Business Wire | bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock | NASDAQ:BLUE | bluebird bio Inc |
| 19/12/2023 | 12:10 | IH Market News | Google $700M Antitrust Settlement, TSMC Chairman Retirement, Tesla Nevada Wage Hike, and More | NASDAQ:BLUE | bluebird bio Inc |
| 18/12/2023 | 22:01 | Business Wire | bluebird bio, Inc. Announces Proposed Public Offering of Common Stock | NASDAQ:BLUE | bluebird bio Inc |
| 10/12/2023 | 18:02 | Business Wire | Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels | NASDAQ:BLUE | bluebird bio Inc |
| 09/12/2023 | 17:31 | Business Wire | Long-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events | NASDAQ:BLUE | bluebird bio Inc |
| 08/12/2023 | 22:11 | Dow Jones News | Bluebird Bio Shares Slide 41% on Black-Box Label, Higher Price for Sickle-Cell Treatment | NASDAQ:BLUE | bluebird bio Inc |
| 08/12/2023 | 19:01 | Business Wire | bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events | NASDAQ:BLUE | bluebird bio Inc |
| 08/12/2023 | 18:35 | Business Wire | bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events | NASDAQ:BLUE | bluebird bio Inc |
| 08/12/2023 | 18:03 | Dow Jones News | Bluebird Bio Gets FDA OK of Lyfgenia Gene Therapy in Sickle-Cell Disease | NASDAQ:BLUE | bluebird bio Inc |
| 07/11/2023 | 13:03 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:BLUE | bluebird bio Inc |
| 07/11/2023 | 13:00 | Business Wire | bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress | NASDAQ:BLUE | bluebird bio Inc |